

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 October 2023 (26.10.2023)



(10) International Publication Number
WO 2023/205661 A3

(51) International Patent Classification:

A61K 35/763 (2015.01) C12N 15/86 (2006.01)
C07K 14/005 (2006.01)

(21) International Application Number:

PCT/US2023/065916

(22) International Filing Date:

18 April 2023 (18.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/331,903 18 April 2022 (18.04.2022) US

(71) Applicant: CANDEL THERAPEUTICS, INC. [US/US];
117 Kendrick Street, Suite 450, Needham, Massachusetts
02494 (US).

(72) Inventors: BARONE, Francesca; c/o 117 Kendrick Street,
Suite 450, Needham, Massachusetts 02494 (US). KRISKY,
David; c/o 117 Kendrick Street, Suite 450, Needham, Mass-
achusetts 02494 (US). DIERS, Anne; c/o 117 Kendrick
Street, Suite 450, Needham, Massachusetts 02494 (US).
WECHUCK, James; c/o 117 Kendrick Street, Suite 450,
Needham, Massachusetts 02494 (US). TAK, Paul Peter;
c/o 117 Kendrick Street, Suite 450, Needham, Massachu-
setts 02494 (US). CHRISTIE, John D.; c/o 117 Kendrick
Street, Suite 450, Needham, Massachusetts 02494 (US).
GUO, Quichen; c/o 117 Kendrick Street, Suite 450, Need-
ham, Massachusetts 02494 (US).

(74) Agent: GUSTAFSON, Megan A. et al.; Goodwin Procter
LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

18 January 2024 (18.01.2024)

(54) Title: COMPOSITIONS AND METHODS FOR VIRAL VECTORS




FIG. 1A

(57) Abstract: The invention relates generally to replication defective HSV-1 vectors, and, more particularly, the invention relates to replication defective HSV -1 vectors comprising an alteration (such as a gene deletion) that prevents expression of one or more infected cell polypeptide 4 (ICP4) and infected cell polypeptide 47 (ICP47) proteins, and their use to deliver one or more genes encoding transgenic proteins that stimulate immune destruction of tumors.

WO 2023/205661 A3